Latar Belakang: Cisplatin, agen kemoterapi utama dalam terapi kanker ovarium,memiliki sifat hepatotoksik karena menginduksi stres oksidatif. Kurkumin dapatmeningkatkan kadar atau aktivitas antioksidan endogen seperti enzim superoksidadismutase dan glutation. Formulasi nanopartikel kurkumin dapat meningkatkanbioavailabilitas kurkumin dan distribusinya pada organ target. Penelitian inibertujuan untuk mengetahui pengaruh nanokurkumin terhadap hepatotoksisitasakibat cisplatin melalui regulasi antioksidan endogen SOD dan GSH. Metode: 25ekor tikus galur Wistar betina dibagi ke dalam 1 kelompok sham dan 4 kelompokmodel kanker ovarium yang diinduksi DMBA pada penelitian in-vivo ini. Empatkelompok tersebut adalah kelompok tanpa terapi, cisplatin 4 mg/KgBBintraperitoneal, cisplatin dengan kurkumin konvensional 100 mg/KgBB per oral,atau cisplatin dengan nanopartikel kurkumin dalam kitosan 100 mg/KgBB per oral.Setelah perlakuan selama 1 bulan, hepar tikus diambil dan disimpan beku.Pengukuran aktivitas SOD, kadar GSH, dan kadar GSSG dilakukan dengan metodespektrofotometri. Hasil: Uji statistik pada kadar GSH, GSSG, dan aktivitas SODmenunjukkan peningkatan yang signifikan pada kelompok ko-kemoterapikurkumin konvensional dibanding monoterapi cisplatin (p<0.05). Tidak adaperbedaan yang bermakna antarkelompok pada rasio GSH/GSSG (p>0.05) dantidak ditemukan perbedaan bermakna antara kedua kelompok ko-kemoterapi padasemua variabel (p>0.05). Kesimpulan: Kurkumin konvensional dan nanokurkuminsetara dalam meregulasi antioksidan endogen SOD dan GSH pada tikus modelkanker ovarium yang mendapat cisplatin.

---

Introduction: As the primary chemotherapeutic agent of choice for ovarian cancer,

cisplatin has hepatotoxic properties via oxidative stress induction. Curcumin can

increase the levels and activities of endogenous antioxidants like superoxide

dismutase enzyme and glutathione. Formulation of curcumin nanoparticles

increases its bioavailability and target organ distribution. This research aims to

elucidate the effects of nanocurcumin on cisplatin-induced hepatotoxicity via

regulation of endogenous antioxidants, SOD and GSH. Method: 25 Wistar female

rats were grouped into 1 sham group and 4 DMBA-induced ovarian cancer model

groups in this in-vivo study. Four cancer model groups were further divided into

no-treatment, 100 mg/KgBW intraperitoneal cisplatin therapy, cisplatin with oral

100 mg/KgBW conventional curcumin, and cisplatin with oral 100 mg/KgBW

curcumin nanoparticle in chitosan group. The liver of the rats were taken and frozen

after one month of treatment. Spectrophotometry was used to measure the activities

of SOD, levels of GSH, and levels of GSSG. Results: Statistic tests on levels of

GSH, GSSG, and activity of SOD showed significant increase in the curcumin cochemotherapy

against cisplatin monotherapy (p<0.05). There was no significant

difference within the groups of GSH/GSSG ratio (p>0.05) and no significant

difference was found between the curcumin co-chemotherapy and nanocurcumin

co-chemotherapy groups in all the variables (p>0.05). Conclusion: Conventional

curcumin and nanocurcumin administration are similar in regulating endogenous

antioxidants SOD and GSH on rats with ovarian cancer model treated with cisplatin.